Floatz logo

Hryz-T101 Tcr-T Cell

Oropharyngeal Cancer

HRYZ Biotech Co.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Oropharyngeal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
HRYZ Biotech Co.
Phase 2BB
Fludarabine
HRYZ Biotech Co.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2B
Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2B
Young Til
National Cancer Institute (NCI)
Phase 2B

View all 23 →

Same molecule, other indications

Hryz-T101 Tcr-T Cell is also rated in:

vaginal neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
penile carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
anal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →